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Holding All the CARDs: How MALT1
Controls CARMA/CARD-Dependent
Signaling
Mélanie Juilland and Margot Thome*
Department of Biochemistry, University of Lausanne, Epalinges, Switzerland
The scaffold proteins CARMA1-3 (encoded by the genes CARD11, -14 and -10) and
CARD9 play major roles in signaling downstream of receptors with immunoreceptor
tyrosine activation motifs (ITAMs), G-protein coupled receptors (GPCR) and
receptor tyrosine kinases (RTK). These receptors trigger the formation of oligomeric
CARMA/CARD-BCL10-MALT1 (CBM) complexes via kinases of the PKC family.
The CBM in turn regulates gene expression by the activation of NF-κB and AP-1
transcription factors and controls transcript stability. The paracaspase MALT1 is the only
CBM component having an enzymatic (proteolytic) activity and has therefore recently
gained attention as a potential drug target. Here we review recent advances in the
understanding of the molecular function of the protease MALT1 and summarize how
MALT1 scaffold and protease function contribute to the transmission of CBM signals.
Finally, we will highlight how dysregulation of MALT1 function can cause pathologies
such as immunodeficiency, autoimmunity, psoriasis, and cancer.
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INTRODUCTION
The past few years have seen considerable advances in our understanding of the role of MALT1
in different biological processes. It is now well accepted that MALT1 acts downstream of various
receptors in a complex composed of CARMA (CARD-containing MAGUK) proteins, the adaptor
protein BCL10 and MALT1 itself. These so-called CBM complexes are crucial for the regulation
of the classical NF-κB pathway (also called canonical or NF-κB1 pathway) and other biological
processes that will be covered in this review. We will first introduce the receptors that signal via
CBM complexes and then describe the role of MALT1 in CBM-dependent signal transmission
and its role in the activation of a variety of downstream signals. Finally, we will highlight how
dysfunction of MALT1 can cause pathological alterations, which may be amenable to treatment
with MALT1 inhibitors that are presently under development.
VARIOUS RECEPTORS SIGNAL VIA CARMA/CARD PROTEINS
AND MALT1
MALT1 is a ubiquitously expressed protease that resides in the cytoplasm as a catalytically inactive
BCL10-bound proenzyme. It is recruited into CBM signaling complexes upon the stimulation
of specific receptors, namely those containing one or more immunoreceptor tyrosine-based
activation motifs (ITAMs), G-protein-coupled receptors (GPCRs), or receptor tyrosine kinases
(RTKs) (Figure 1) (1).
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Various immunoreceptors of the innate and adaptive immune
response activate MALT1. A common feature of such receptors
is the presence of one or more ITAMs, which is crucial for
transmembrane signal transmission (2). The ITAM can be
present in the cytoplasmic tail of the immunoreceptors, as
is the case for the zymosan receptor Dectin-1 present on
dendritic cells (DC), or the FcεRI on mast cells. Alternatively,
the ITAM can be present in a receptor-associated signaling
subunit. For example, in CD3 chains associated with the
T-cell receptor (TCR), the CD79 chains associated with the
B-cell receptor (BCR) and the FcRγ chain associating with the
myeloid cell receptor Dectin-2 or the natural killer (NK) cell
receptors NK1.1/Ly49D/Ly49H/NKG2D (2, 3). Upon receptor
triggering, Src family kinases phosphorylate the ITAMs, thereby
providing a docking site for Syk family kinases. Once recruited,
Syk kinases induce the downstream signaling events, which
converge toward the activation of PKC family kinases, PKC-
dependent phosphorylation of the CARMA/CARD protein and
the subsequent formation of a CBM complex, for which the
composition is specific for different receptor types (Figure 1).
A common feature of all receptors signaling via CBM
complexes is the use of MALT1 as a scaffold protein for the IKK-
dependent activation of the heterodimeric transcription factors
of the NF-κB1 subtype, p50-RelA and p50-cRel (referred to
as NF-κB). As a scaffold protein, MALT1 binds the ubiquitin
ligase TRAF6, which subsequently modifies itself, BCL10, and the
IKK subunit NEMO by K63-linked polyubiquitin chains (4–7).
These modifications are required for the downstream activation
of the IKK complex (4, 6), which phosphorylates the NF-κB
inhibitor, IκBα, to trigger its proteasomal degradation (8, 9). The
protease activity of MALT1 makes an additional contribution to
the intensity and persistence of the NF-κB response by cleaving
the proteins A20 and RelB, which act as negative regulators of
NF-κB activation (10, 11). However, whether all CBM-dependent
Abbreviations: ABC, activated B-cell; AGTR1, angiotensin II receptor; ATLL,
adult T-cell leukemia/lymphoma; BCL10, B-cell lymphoma-10; BCR, B-cell
receptor; BENTA, B-cell expansion with NF-κB and T-cell anergy; CARD,
caspase recruitment domain; CARMA, CARD-containing membrane-associated
guanylate kinase; CBM, CARMA/CARD-BCL10-MALT1; CC, coil-coiled; CDE,
constitutive decay element; CLL, chronic lymphocytic leukemia; CTCL, cutaneous
T-cell lymphoma; DD death domain; DC, dentritic cells; DLBCL, diffuse large
B-cell lymphoma; DUB, deubiquitinating enzyme; EGFR, epidermal growth
factor receptor; FcR, Fc receptor; FLIP, Flice-like inhibitory protein; GPCR,
G protein-coupled receptor; GUK, guanylate kinase; HER2, human EGFR-2;
HOIL1, heme-oxidized IRP2 ubiquitin ligase 1; HOIP, HOIL1-interacting protein;
HHV8, human herpes virus-8; Ig, Immunoglobulin; IPEX, immune dysregulation,
polyendocrinopathy, enteropathy, X-linked; ITAM, immunoreceptor tyrosine-
based activation motif; KSHV, Kaposi’s sarcoma-associated herpes virus; LMP2A,
latent membrane protein 2A; LUBAC, linear ubiquitin chain assembly complex;
Mϕ, macrophage; MAGUK, membrane-associated guanylate kinase; MALT,
mucosa-associated lymphoid tissue; MC, myeloid cell; MCL, mantle cell
lymphoma; mTORc1, mammalian target of rapamycin complex 1; MZ, marginal
zone; nTreg, natural Treg; JNK, c-Jun N-terminal kinase; NF-κB, nuclear factor
kappa B; NK, natural killer; OSCAR, osteoclast associated receptor; PDZ, PSD95
Dlg1 ZO-1; PEL, primary effusion lymphoma; PI, protease inactive; PKC, protein
kinase C; PTCL, peripheral T-cell lymphoma; RTK, receptor tyrosine kinases;
TCR, T cell receptor; TREM-1, triggering expression by myeloid cells 1; PTM,
posttranslational modification; RA, rheumatoid arthritis; SH3, Src homology 3;
SHARPIN, SHANK-associated RH domain interacting protein; UTR, untranslated
region.
signaling pathways rely on the protease activity of MALT1, or
whether some receptors only rely on the MALT1 scaffold activity
remains poorly understood.
The relevance of MALT1 protease activity is strongly
evidenced for ITAM-containing receptors, which promote
activation of lymphoid and NK cells via CARMA1/CARD11
(11–13) and myeloid cells via CARD9 (13, 14). The protease
activity ofMALT1 also plays a role outside the immune system, in
the activation of keratinocytes (15). Stimulation of keratinocytes
with zymosan, which triggers the ITAM-containing receptor
Dectin-1, leads to CBM complex activation and MALT1 protease
activity via CARMA2/CARD14. This suggests that all ITAM
containing receptors signal via both the scaffold and protease
activity of MALT1 in immune and non-immune cells.
A variety of GPCRs (such as AT1R, Par-1, PAFR, ETA,
ETB, CXCR2, CXCR4, LPA1-6) and RTKs (the EGFR and
HER2/neu) have been shown to trigger the formation of a CBM
complex comprising CARMA3/CARD10 (Figure 1) [see (1) and
references therein]. Whether the protease function of MALT1
is involved or not in the transmission of the signaling pathway
of these receptors is not well understood. For one GPCR (the
thrombin receptor PAR1), the protease activity of MALT1 was
found to be crucial for the regulation of the integrity of epithelial
barriers, whereby stimulation of epithelial cells with thrombin
lead to MALT1 proteolytic activity and CYLD cleavage (16),
in addition to the previously described formation of a CBM
complex comprising CARMA3 (17). These findings suggest the
possibility of a broader involvement of the protease activity
of MALT1 in CBM-dependent GPCR signaling. In contrast,
signaling via the human EGFR2 (HER2), a receptor tyrosine
kinase (RTK), has been proposed to depend mainly on the
scaffold activity of MALT1 (18). It is possible that MALT1 cleaves
a distinct subset of substrates in epithelial cells, or that MALT1
activation requires co-stimulation of the EGFR and another,
yet to be identified co-receptor. A need for co-stimulation is
observed in T cells, where optimal CBM complex assembly and
activation of MALT1 protease activity requires the synergistic
stimulation of both, the TCR and the costimulatory receptor
CD28 (11, 12, 19, 20). Whether MALT1 protease activity is
activated downstream of RTK merits further exploration.
MULTIPLE ELEMENTS CONTROL THE
ASSEMBLY AND ARCHITECTURE OF THE
CBM COMPLEX
A common feature of receptors that signal via MALT1 is their
capacity to induce the formation of a specific type of CBM
signaling complex. In resting cells, the members of the CBM
complex reside in an inactive form in the cytoplasm. The
catalytically inactive proenzyme MALT1 binds constitutively
to BCL10, while the CARMA/CARD scaffold proteins are
kept in a monomeric inactive form due to intramolecular
inhibitory interactions. The inducible assembly of the CBM
complex requires specific protein domains present in each
CBM component (Figure 2). The CARD proteins CARMA1
(CARD11), CARMA2 (CARD14), and CARMA3 (CARD10)
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FIGURE 1 | Signaling via MALT1 downstream of various receptors and CARMA/CARD proteins. CBM complexes composed of MALT1, BCL10 and the indicated
CARMA/CARD proteins are formed downstream of receptors containing immunoreceptor tyrosine-based activation motifs (ITAMs), G-protein-coupled receptors
(GPCRs) or receptor tyrosine kinases (RTKs). Once formed, the CBM complex activates downstream signaling events via the scaffold and protease function of
MALT1. The CBM complex of T and B cells is best characterized, while CBM complexes in other cellular contexts are less well studied. Open questions that remain to
be addressed are annotated with a red question mark. Deregulated activation of the pathway results in different diseases, as summarized in the lower panel of the
figure. BCR, B cell receptor; DC, dendritic cell; EGFR, epidermal growth factor receptor; FcR, Fc receptor; Mϕ, macrophage; MC, myeloid cell; NK, natural killer;
OSCAR, osteoclast associated receptor; PKC, protein kinase C; TCR, T cell receptor; TREM-1, triggering expression by myeloid cells 1; RA, rheumatoid arthritis.
are structurally similar. Each contains an N-terminal CARD,
followed by a coil-coiled (CC) domain and a C-terminal
region that shares features with proteins of the membrane-
associated guanylate kinase (MAGUK) family, which contain a
PDZ (PSD95, Dlg1, ZO-1), SH3 (Src homology 3), and GUK
(guanylate kinase) domain. CARD9 contains a CARD and coiled-
coil motif but lacks the C-terminal MAGUK features (21–25). An
important structural feature of BCL10 is its N-terminal CARD
that allows its inducible association with a CARMA/CARD
component (21–25). Additionally, BCL10 contains a C-terminal
region with a short sequence of amino acids (107-118) that is
necessary for its constitutive interaction with MALT1 (21, 26).
MALT1 contains an N-terminal death domain (DD) of unknown
function, followed by two immunoglobulin (Ig)-like domains
required for BCL10 binding, a caspase-like protease domain and
a third Ig domain that plays a regulatory role for the protease
function (27, 28) (Figure 2).
The inducible assembly of the CBM complexes seems to
depend on a common, conserved mechanism that requires the
receptor-induced activation of PKC family members (29, 30).
These Ser/Thr kinases (and likely other kinases) phosphorylate
the CARMA/CARD proteins in the linker region (Figure 2,
illustrated here for CARMA1 (CARD11)) (29–31). This in turn
is thought to weaken an inhibitory intra-molecular interaction
between the CARD and linker domain, thereby promoting a
CARD-mediated association with BCL10 and the formation of
the CBM complex (29–31). Similar mechanisms are thought to
control activation of CARMA3 (26), CARMA2 (15), and CARD9
(32), but whether PKC family members directly phosphorylate
CARMA2 or CARMA3 is not known. CBM complex formation
depends on homotypic CARD-CARD interactions between the
CARMA/CARDproteins and BCL10 (21–23, 25, 26) and possibly
on an additional interaction of the protease domain of MALT1
with the CC domain of CARD proteins as was demonstrated
for CARMA1 (33). The CC region of CARMA1 has been shown
to mediate oligomerization that is required for TCR-induced
NF-κB activation (30, 34). Structural architecture studies and
modeling suggest that the CC domain-mediated oligomerization
of CARMA1 nucleates the oligomerization of BCL10 into helical
filaments. BCL10 filaments are formed in a cooperative manner
and stabilized through homotypic interactions formed between
the CARD motifs of adjacent BCL10 monomers in the filament
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FIGURE 2 | Structure and function of the CBM complex. In resting conditions,
MALT1 and BCL10 interact constitutively, while CARMA1 is dissociated from
the other components of the CBM. PKC-mediated phosphorylation triggers a
conformational opening and oligomerization of CARMA1, leading to the
recruitment of preformed MALT1- BCL10 complexes. The E3 ligase TRAF6 is
further recruited and polyubiquitinates MALT1 and BCL10. This favors the
recruitment of the IKK and TAB2/3-TAK1 complexes and the downstream
activation of NF-κB and AP-1. N-terminal phosphorylation of BCL10 by IKKβ
enhances NF-κB activation, while a C-terminal phosphorylation disassembles
MALT1 from BCL10. BCL10 can undergo both, linear polyubiquitination and
K63-linked polyubiquitination, which are important for IKKγ/NEMO recruitment.
Monoubiquitination activates MALT1 protease function. Once activated,
MALT1 cleaves several substrates including BCL10 (after R228) and itself (after
R149). The CBM signal is thought to be amplified by formation of filamentous
BCL10 structures initiated by CARMA1 nucleation. BCL10 filaments are
decorated with MALT1, most likely in its dimeric form. Double-headed arrows
indicate interactions. Arrows indicate P, phosphorylations; Ub, ubiquitination.
(35). MALT1 is constitutively associated with BCL10, and
therefore forms part of these filamentous structures (Figures 2,3)
(35). Although not filamentous in nature, oligomeric signaling
complexes containing proteins with CARD motifs, such as
the apoptosome, inflammasome, and pyddosome, have been
proposed to be key to the activation of proteases of the caspase
family (36). Therefore, a prime purpose of the formation of
BCL10-MALT1 filaments is likely to allow the oligomerization-
dependent activation of MALT1. Crystallographic data from
several groups support the idea that active MALT1 forms a
dimer that is stabilized by interactions between the protease
domain (37, 38). It is tempting to speculate that BCL10 filaments
form a scaffold that permits additional interactions between
MALT1 dimers leading to its proteolytic activation (Figure 2).
MALT1 activation strictly requires monoubiquitination in its Ig3
domain that promotes its activation in an intra-or intermolecular
manner (39). Exactly how this monoubiquitination contributes
toMALT1 activation within the context of the oligomeric BCL10-
MALT1 fibers remains unexplored. Although this has not yet
been formally addressed, it is likely that similar oligomerization-
dependent protein complexes control CBM-driven signaling for
all CARMA/CARD proteins.
MALT1 FUNCTION IS DETERMINED BY ITS
MULTIDOMAIN STRUCTURE
The MALT1 gene was originally identified as the target of
recurrent translocations in MALT lymphomas (40–42). Later on,
in silico studies uncovered that MALT1 shares homology with
caspases and metacaspases and therefore falls into a category of
caspase-like proteases coined paracaspases (27, 43). The partial
structure of the MALT1 caspase-like domain together with the
third Ig domain has been recently solved and confirms the
expected structural similarities between the protease domains of
MALT1 and caspases (37, 38).
Apart from sharing structural homology, several other
aspects of MALT1 function are shared with caspases, including
cysteine-dependent protease activity (11, 12) a requirement for
dimerization (38, 44), and the capacity to auto-process (45, 46).
Like caspases,MALT1 contains a protease domain with a catalytic
dyad comprising two amino acids that are essential for catalysis,
namely C464 and H415 (27). Monomeric MALT1 is inactive
and, as for caspases, requires dimerization via the caspase-like
protease domain for enzymatic activity (38, 44, 47) (Figure 3B).
Interestingly, MALT1 has been recently shown to undergo
autoprocessing. However, unlike caspases, which autoprocess
within the protease domain, MALT1 cleaves itself between the
N-terminal death domain and the first Ig domain (45, 46). This
does not seem to enhance proteolytic activity but is essential for
MALT1-dependent NF-κB activation by a mechanism that is not
yet understood (45, 46). In contrast to caspases, the proportion
of cellular MALT1 undergoing autoprocessing is very small. It
is unclear whether this reflects activation of only a very small
proportion of cellular MALT1 or a subtler regulation of its
activity, which needs to be investigated in more detail.
Despite the above-mentioned structural similarities between
caspases and MALT1, several important differences exist. One
major difference between caspases and MALT1 resides in their
substrate specificity. While caspases are aspartic acid-specific
proteases, MALT1 cleaves its substrates after arginine residues
(11, 12, 47). The consensus cleavage site of MALT1 based on
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FIGURE 3 | MALT1 scaffold and protease functions. (A) Antigen receptor triggering leads to the formation of the CBM complex that acts as a recruiting platform for
the ubiquitin ligase TRAF6 and the linear ubiquitin chain assembly complex (LUBAC). TRAF6-dependent K63-linked polyubiquitination promotes IKK complex
activation by recruiting TAB2/3 together with TAK1 into proximity of the IKK complex. The TAB2/3-TAK1 complex also promotes AP-1 signaling through MKK7 and
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known substrates and screening of a tetrapeptide library, is a
peptide sequence composed of an arginine at the P1 position,
which is in most cases followed by a G or A residue. A
hydrophobic residue is usually present at position P4, a rather
variable range of amino acids is tolerated at P3 and a preference
for serine or proline was found for position P2 (47). The
consensus cleavage site could thus be summarized as follows:
Φ-X-P/S-R’-G/A.
A second important difference between caspases and MALT1
concerns the regulation of MALT1 function, which is dependent
on posttranslational modification (PTM) by ubiquitination.
MALT1 is ubiquitinated, upon antigen receptor triggering,
within the Ig3 domain and its C-terminal part by either
K63-linked polyubiquitination or monoubquitination. MALT1
polyubiquitination mediated by TRAF6 is crucial for the
activation and/or physical recruitment of the IKK complex,
which phosphorylates the NF-κB inhibitor IκB to initiate its
degradation and thus allows the nuclear translocation of NF-
κB (4, 6, 7). This K63-linked polyubiquitination of MALT1
likely provides docking sites for the adaptor protein TAB2,
which forms a complex with the IKK-activating kinase TAK1
(48). Additionally, the K63-linked ubiquitin chains may serve
to physically recruit the IKK complex via its catalytically
inactive IKKγ subunit (4, 49). MALT1 mono-ubiquitination
on lysine residue 644 (K644), on the other hand, is required
for the activation of MALT1 protease activity, most likely
by favoring the formation of an active dimeric form of
MALT (39).
A third aspect that differentiates MALT1 from caspases is
the specific presence of additional protein domains that support
its regulation and function. In the N-terminal part preceding
the protease domain, MALT1 contains an N-terminal death
domain (DD) followed by two Ig-like domains. The C-terminal
part following the caspase-like domain contains a third Ig-like
domain and a structurally undefined (most likely flexible) C-
terminal extension (Figure 2). DDs can serve as protein-protein
interaction domains in apoptotic signaling pathways. However,
and despite its structural similarity with caspases, MALT1 does
not induce apoptosis. This suggests that the MALT1 DD recruits
another, yet to be identified, DD-containing protein unrelated
to apoptosis. It is also possible that this domain plays an
inhibitory role, since MALT1 autoprocessing, which removes
the DD, is required for optimal NF-κB activation (45, 46).
Additional unique features of MALT1 are the presence of three
Ig domains that contribute to protein-protein interactions, and
the presence of TRAF6 binding motifs. The first two Ig domains
of MALT1 are necessary for the binding to BCL10 and are
therefore crucial for its ability to induce CBM-mediated NF-
κB activation upon engagement of the TCR (24). The region
between the second Ig domain and the caspase-like domain
contains a motif that is important for TRAF6 binding (4, 5),
which is lacking in a recently described MALT1 splice variant
(see below) (50) (Figure 2). Additional TRAF6 binding sites are
present in the C-terminal extension, which are important for
the downstream signaling event (4). The third, C-terminal Ig
domain interacts physically with the protease domain and has
Frontiers in Immunology | www.frontiersin.org 5 August 2018 | Volume 9 | Article 1927
Juilland and Thome MALT1 and CBM Signaling
a particularly important role in MALT1 protease activity, which
is regulated by mono-ubiquitination (Figure 2) (39). This and
other posttranslational modifications of MALT1 and the CBM
complex are important for downstream signaling events that will
be discussed below.
THE CBM COMPLEX FORMS A
SCAFFOLDING PLATFORM FOR PROTEIN
RECRUITMENT
Once assembled, the CBM complex acts as a signaling platform
for the recruitment of multiple signaling complexes, including
TRAF6, the TAB1/2-TAK1 complex, the IKK complex, and the
linear ubiquitin chain assembly complex (LUBAC) (51). These
control various aspects of signal transmission that are essential
for NF-κB and AP-1 activation.
The activation of NF-κB requires both the physical
recruitment of the IKK complex and its activation by the
Ser/Thr kinase TAK1. Recent data suggest an important role
for both TRAF6 and the LUBAC complex in promoting IKK
recruitment (4, 52). The LUBAC complex is composed of three
subunits known as HOIL1 (heme-oxidized IRP2 ubiquitin
ligase 1), HOIP (HOIL1-interacting protein; also known as
RNF31), and SHARPIN (SHANK-associated RH domain
interacting protein). The HOIP subunit has an E3 ligase activity,
while HOIP and SHARPIN are important for LUBAC complex
regulation, such as assuring its proper localization or stability
(52, 53). The CBM complex can associate with the LUBAC
complex in a transient manner in stimulated T cells, with
kinetics that are similar to the association of LUBAC with the
IKK complex (54). The stimulation-induced phosphorylation
and conformational opening of CARMA1 is thought to lead
to recruitment of both, BCL10 and HOIP (55). BCL10 thereby
becomes accessible for HOIP-mediated linear ubiquitination on
K17, K31, and K63 residues (55). The linear ubiquitination of
BCL10 may promote NF-κB activation by providing docking
sites for the physical recruitment of NEMO/IKKγ via its UBAN
domain (55). However, alternative mechanisms may contribute
to IKK recruitment, since another study showed a role for
the LUBAC complex in optimal NF-κB activation that was
independent of HOIP’s ubiquitin ligase activity (54). Indeed, K31
and K63 on BCL10 can be subject to both linear or K63-linked
polyubiquitination (7, 55) and the BCL10 modification by
K63-linked ubiquitin chains may also contribute, although
with lower affinity, to the physical recruitment of NEMO/IKKγ
(7, 49, 56).
The CBM-associated E3 ubiquitin ligase responsible for
synthesis of K63-linked ubiquitin chains is TRAF6, which
associates with oligomeric BCL10-MALT1 complexes (4)
and can be physically incorporated into the BCL10-MALT1
filaments in a cooperative manner (57). It has therefore
been proposed that BCL10-MALT1 oligomers serve to
activate TRAF6 to promote the ubiquitination-dependent
activation of the IKK complex (4) (Figure 3). MALT1 is
polyubiquitinated by TRAF6 on multiple sites preceding the
protease domain and within the Ig3 domain (Figure 2). These
polyubiquitination events are critical for NF-κB activation,
since mutation of key amino acids important for TRAF6
binding to MALT1 impairs TCR-induced NF-κB activation
(4, 5, 50). The TRAF6-mediated polyubiquitination of MALT1
and/or itself is thought to recruit the TAB2/3-TAK1 complex
(4), since the adaptor proteins TAB2/3 contain ubiquitin-
binding motifs that bind to K63 polyubiquitin chains (58).
TAK1, which associates with TAB2/3, is thereby brought into
proximity of the IKK complex to phosphorylate the IKKβ
subunit. IKKβ phosphorylation activates the IKK complex,
which phosphorylates the NF-κB inhibitor IκB, inducing its
degradation to allow nuclear entry of NF-κB (4). In parallel,
TAK1 contributes to AP-1 activation via theMKK7-JNK pathway
(Figure 3) (59).
Interestingly, a recent study suggests a novel regulatory
mechanism for MALT1-dependent TRAF6 recruitment by
alternative splicing of MALT1 (50). In primary T cells, two
MALT1 isoforms can be expressed, namely MALT1A or
MALT1B, the latter of which lacks 11 amino acids encoded by
exon 7 (50). These 11 amino acids encode for the first TRAF6
binding site, localized between the second Ig like domain and
the paracaspase domain of MALT1 (5, 50) (Figure 2). Resting
primary T cells express MALT1B, while MALT1A expression
is induced upon TCR triggering (50). Therefore, TCR-induced
expression of MALT1A likely reinforces the TRAF6-recruiting
scaffolding function of the CBM complex (50).
Collectively, these findings support the notion that formation
of the CBM complex has a key role in signal transmission as a
protein recruitment scaffold.
THE CBM COMPLEX PROMOTES MALT1
PROTEOLYTIC ACTIVITY
The above-described steps of protein recruitment downstream
of the CBM complex are most likely early signaling events
that occur within the first minutes of lymphocyte stimulation,
since peak IκB phosphorylation is detectable within a few
minutes after antigen receptor engagement. The scaffolding
function of MALT1 may then be amplified and propagated
by its assembly with the BCL10 filamentous structures that
are nucleated by CARMA1, as depicted in Figures 2, 3.
The activation of the MALT1 protease activity most likely
depends on further amplification of the signal through filament
formation, since optimal MALT1 activity is detectable later
than IKK activation, and peaks roughly 30min after antigen
receptor engagement (11, 12, 19, 20). How exactly filament
formation could contribute to MALT1 activation remains
unknown. Interestingly, monoubiquitination on K644 within
the Ig3 domain of MALT1 is required to license MALT1
protease activity (39). Indeed, a point mutation of K644
preventing monoubiquitination of MALT1 has strongly reduced
protease activity and an impaired capacity to sustain IL-2
production in activated T cells (39). The incorporation ofMALT1
into filaments might promote MALT1 activation in various
ways, for example by allowing recruitment of the (unknown)
ubiquitin ligase responsible for MALT1 monoubiquitination
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and/or assuring physical proximity between MALT1 and its
substrates (Figure 3).
MALT1 CLEAVES VARIOUS SUBSTRATES
WITH DIVERSE BIOLOGICAL
CONSEQUENCES
The last 10 years have witnessed impressive progress in the
understanding of MALT1 protease function and its role in
NF-κB- dependent and -independent aspects of lymphocyte
activation. The best-explored function of MALT1 protease
activity is its contribution to NF-κB activation. While MALT1
scaffold-dependent IKK activation promotes rapid but transient
NF-κB activation, long-lasting NF-κB activation is assured by
the MALT1-dependent cleavage of negative regulators of NF-κB,
including RelB (10) and A20 (11), together with MALT1
autoprocessing (45, 46) (Figure 3). RelB plays a critical role as
an inhibitor of the canonical NF-κB pathway in lymphocytes,
by forming transcriptionally inactive complexes with RelA and
c-Rel (10). MALT1-dependent RelB cleavage results in RelB
proteasomal degradation, thereby favoring RelA-, and c-Rel-
dependent NF-κB activation (10). MALT1-dependent cleavage
of the deubiquitinating enzyme (DUB) A20, on the other hand,
relieves its inhibitory role in NF-κB activation (11). How exactly
A20 cleavage promotes NF-κB activation remains incompletely
understood. It has been proposed that A20 negatively regulates
the scaffolding function of MALT1 by removing the MALT1
polyubiquitination (60), however this function of A20 does not
seem to be affected by its cleavage, since MALT1 inhibitors do
not affect IKK-mediated NF-κB activation. A third cleavage event
that is important for NF-κB activation is MALT1 autoprocessing
(45, 46). MALT1 is autoprocessed after R149, between the N-
terminal DD and the first Ig domain. This cleavage is essential
for NF-κB activation downstream of its nuclear accumulation
by mechanisms that are not yet elucidated (Figure 2) (45).
Finally, NF-κB can be negatively regulated by the recently
identified MALT1 substrate HOIL1, which is part of the LUBAC
complex (61, 62). HOIL1 cleavage by MALT1 diminishes linear
ubiquitination of cellular proteins, and has thus been proposed
to provide negative feedback on the NF-κB pathway (61, 62).
Another important transcriptional pathway that is regulated
by MALT1 is the JNK/AP-1 pathway. While the scaffold function
of MALT1 is required for JNK activation (63), the protease
activity of MALT1 provides an additional layer of control, via the
cleavage of the deubiquinating enzyme (DUB) CYLD (64). CYLD
cleavage is unlikely to affect JNK activation, since MALT1 knock-
in mice showed no defect in inducible JNK phosphorylation
(13, 14, 65, 66), Thus, CYLD cleavage regulates AP-1 through
another mechanism that remains to be explored (Figure 3).
Despite the described role of CYLD in the negative regulation
of NF-κB and the fact that CYLD shares certain substrates with
A20 (such as TRAF2, TRAF6, RIP1, and IKKγ) (67), CYLD
cleavage is not implicated in TCR-dependent canonical NF-κB
activation (64).
Several studies have identified additional NF-κB- and AP-
1 independent roles for MALT1. One of these roles is the
control of the stability of particular subsets of mRNA transcripts.
The MALT1-dependent cleavage of the RNAse Regnase-1 (also
known as MCPIP-1 or Zc3h12a) (68) and of the two RNA
binding proteins Roquin-1 and Roquin-2 (69) has been shown to
stabilize mRNAs by distinct mechanisms. Regnase-1 is an RNAse
that cleaves stem loop structures in the 3′ untranslated region
(UTR) of mRNAs, including the mRNAs of Regnase-1 itself, c-
Rel, ICOS, OX40, IL-2, and IL6 (70). T cell specific Regnase-
1 knockout mice developed spontaneous inflammation and
premature death, demonstrating the crucial role of Regnase-1 in
the regulation of mRNA stability during the adaptive immune
response (68). Roquin-1 and Roquin-2 proteins bind to mRNAs
via their ROQ domain, which recognizes a secondary RNA
structure called constitutive decay element (CDE), and regulate
gene expression at the posttranscriptional level (71). Roquin-1
and its paralog Roquin-2 are functionally interchangeable (72).
To degrade mRNAs, Roquins recruit an mRNA deadenylase
complex via their C-terminal part (71) and regulate the half-
life of key cytokines, chemokines, and costimulatory proteins
such as ICOS, OX40, and TNF (71, 73, 74). Similar to Regnase-
1 deficient mice, Roquin mutant mice (expressing a Roquin
mutant that cannot bind CDEs), develop autoimmunity (73).
Regnase-1 and Roquins regulate mRNA decay of common
and Regnase-1- or Roquin-specific mRNAs. During T cell
triggering, the combined mRNAse activity of Regnase-1 and
the mRNA decay activity of Roquins are overcome by their
MALT1-dependent cleavage and degradation (Figure 3) (68,
69).
Finally, the protease activity of MALT1 also regulates
transcription-independent cellular functions by the cleavage
of BCL10, which promotes lymphocyte adhesion through β1
integrins (11, 12, 19, 20). MALT1-mediated BCL10 cleavage
removes 5 amino acids from its C-terminus (11, 12, 19, 20). This
cleavage is not required for antigen-dependent NF-κB activation
but is important for integrin-mediated T-cell adhesion (11, 12, 19,
20). The molecular mechanisms controlling adhesion via BCL10
remain elusive (Figures 2, 3).
Thus far, 8 different substrates of MALT1 have been
functionally described in activated lymphocytes, and two
additional substrates (NIK and LIMA1) have been reported
as specific substrates of an oncogenic cIAP2-MALT1 fusion
protein specifically expressed in MALT lymphoma (75, 76). We
can therefore reasonably anticipate that MALT1 has additional
substrates with functions that are much wider than anticipated.
For example, MALT1 protease function has been suggested to
play a key role in metabolic pathways (77). Glutamine uptake
is rapidly initiated upon naive T cell activation via the amino
acid transporter ASCT2 and this uptake is crucial for activation
of the mammalian target of rapamycin complex 1 (mTORc1).
Interestingly, both glutamine uptake and mTORc1 activation
required proteins of the CBM complex and MALT1 protease
activity (77). This suggests a novel role for the MALT1 protease
function in the regulation of glutamine uptake via the regulation
of mTORc1 and/or ASCT2 (77). Whether this regulation is
mediated by one of the already described substrates of MALT1,
or whether a yet unidentified MALT1 substrate can modulate the
mTORc1 signaling pathway remains to be explored.
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MICE LACKING MALT1 EXPRESSION OR
ACTIVITY HAVE DISTINCT
IMMUNOLOGICAL PHENOTYPES
The protease activity and most of the substrates of MALT1
have been initially identified and characterized in cell lines.
However, recent studies using mouse models have lent strong
support to the physiological relevance of MALT1 protease
activity in adaptive immunity. MALT1-deficient mice show
impaired B- and T-cell responses together with defects in the
development of particular lymphocyte subsets such as marginal
zone (MZ) and B1 B cells (63, 78). Moreover, these mice are
resistant to experimental induction of experimental autoimmune
encephalitis, a mouse model of multiple sclerosis (79, 80). Mice
expressing a catalytically inactive mutant of MALT1 [C472A
knock-in mice, subsequently called MALT1-protease inactive
(PI) mice] recapitulate these aspects of the immunodeficiency
phenotype of the MALT1 knockout mice to a large extent.
Lymphocytes isolated from the MALT1-PI mice also revealed
defects in NF-κB activation, AP-1 activation, mRNA stability
and lymphocyte adhesion that are all consistent with previous
studies from cell lines (13, 14, 65, 66, 81). Despite these
impaired responses, the lymphocytes isolated from MALT1-PI
mice showed normal antigen receptor-mediated activation of
IKK or JNK (63, 78). The impaired cellular responses and the
associated immunodeficiency phenotype of the MALT1-PI mice
results thus principally from the inactivation of the proteolytic
activity of MALT1.
In addition to defects in T- and B-cell responses, MALT1-
deficient mice have impaired myeloid and mast cell responses
upon Fc-receptor stimulation, reduced NK cell responses and
defective innate immunity to yeast infections (63, 78, 82–84).
The cellular responses of myeloid and NK cells have
also been assessed in MALT1-PI mice and found to be
defective.
A surprising finding of all four studies reporting MALT1-
PI mice, however, is that these mice develop autoimmune
symptoms, in particular a severe autoimmune gastritis of early
onset, which progresses with age (13, 65, 66). The observed
autoimmunity is likely the result of reduced development of
natural Treg (nTreg) cells in MALT1-PI mice (13, 65, 66).
Indeed, the autoimmune phenotype of MALT-PI mice can
be rescued through transfer of wildtype Tregs into newborn
MALT1-PI animals (13, 65). An even stronger reduction of
nTregs is found in MALT1-deficient mice (13, 65, 66). However,
MALT1-deficient mice show no autoimmune pathology, most
likely because their lymphocyte responses are more dramatically
affected (13, 14, 63, 65, 66). The reduced Treg numbers
are likely caused by the absence of MALT1 function during
development, since no spontaneous autoimmunity develops in
adult mice treated with small molecule MALT1 inhibitors for
up to 17 days (85). Indeed, young MALT1-PI mice do not
show autoimmune features and are completely resistant to
induction of experimental autoimmune encephalitis (13, 65).
While the contribution of individual MALT1 substrate(s) to
nTreg development remains largely unknown, a recent study
suggests that MALT1 autoprocessing is important for nTreg
development (46). Indeed, mice expressing an autoprocessing-
resistant mutant of MALT1 have a partial Treg deficit that
results in enhanced anti-tumor immunity without causing
autoimmunity (46).
Mice deficient for the individual CARMA/CARD family
members have additional phenotypic features, including a
defect in innate immune responses against bacteria, fungi
or viruses in CARD9 KO mice (82, 86, 87) and a specific
defect in NF-κB signaling upon stimulation of GPCRs in
CARMA3-deficient mice (88). Whether these phenotypes
depend on MALT1 protease activity remains largely unexplored.
In addition, roughly half of CARMA3- and one third of
BCL10-deficient mice die prematurely due to a neuronal tube
defect, suggesting a common role for CARMA3 and BCL10
in embryonic development (88, 89). This defect is neither
present in MALT1-deficient nor in MALT-PI mice and therefore
likely depends on MALT1-independent signaling features of
CARMA3 and BCL10. CARMA2/CARD14-deficient mice
have been recently generated and found to be resistant to
psoriasis induction by imiquimod cream or recombinant IL-23
injection (90). The individual contributions of keratinocytes
and γδ T cells to the CARMA2/CARD14 dependent-
inflammation and the extent to which MALT1 protease activity
contributes to inflammatory skin reactions remain to be further
investigated.
MALT1 DEREGULATION IS ASSOCIATED
WITH IMMUNODEFICIENCY AND
LYMPHOMA
A deregulation of MALT1 function is associated with the
development of various diseases. Patients with inactivating
MALT1 mutations develop immunodeficiency (91–93) or
immune dysregulation, polyendocrinopathy, enteropathy,
and X-linked (IPEX)-like syndrome (94). Patients with
an oncogenic activation of the MALT1 signaling pathway,
on the other hand, develop lymphoid malignancies or
lymphoproliferative disease (Figures 1,4) (95, 96). An
increasing number of T and B cell malignancies are now
recognized to be driven by constitutive antigen receptor
signaling as a result of foreign or self-antigen recognition
(97) and/or gain-of function mutations (Figures 4A,B) that
trigger CBM complex formation and downstream signaling
(95, 98–104). Such mutations can be found in the CBM
component CARMA1 itself (98) or in the upstream components
of the pathway, including the B-cell receptor-associated
CD79 chains (103), the T-cell coreceptor CD28, PLCγ1
and PKCβ (95). Lymphomas with such mutations include
the activated B-cell (ABC) subtype of diffuse large B-cell
lymphoma (DLBCL) (98, 99, 103, 105, 106), in which chronic
active BCR signaling is often combined with oncogenic
activation of the TLR signaling component MyD88 (107).
Constitutive CBM-dependent signaling is also found in mantle
cell lymphomas (MCL) (104, 108, 109), chronic lymphocytic
leukemia (CLL) (110), acute T-cell leukemia/lymphoma
(ATLL) (102), cutaneous T-cell lymphoma (CTCL) and Sézary
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FIGURE 4 | CARMA/CARD-dependent and-independent MALT1 activation. (A) In the depicted T cell malignancies, gain-of-function mutations in CARMA1 or its
upstream regulators or in-frame gene fusions of the T-cell co-receptor CD28 with ICOS or CTLA-4 are thought to promote MALT1 constitutive activation. (B) In the
indicated B-cell lymphomas constitutive MALT1 protease activity can be driven by oncogenic mutations in CARMA1, CD79A or CD79B, which may be relevant in
combination with self-antigen recognition. A subset of MCL and CLL are also addicted to this pathway by unknown mechanisms. (C) A large proportion of MALT
lymphoma harbors a chromosomal translocation leading to formation of an oncogenic MALT1-API2 fusion protein. (D) In primary effusion lymphoma (PEL), NF-κB is
activated through viral latency proteins such as K13 and K15, which activate NF-κB directly or via MALT1-BCL10. (A,B), mutations and self-antigen are depicted with
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lymphocytic/leukemia.
syndrome (100, 101), as well as peripheral T-cell lymphomas
(PTCL) (111) (Figures 4A,B). The relevance of the CBM
complex and MALT1 protease activity were formally shown
by silencing of the individual CBM components in ABC
DLBCL (112, 113) and MCL (104) cell lines, or by inhibition of
MALT1 proteolytic function in ABC DLBCL (113, 114), MCL
(104), and CLL (110) cell lines. Interestingly, gain of function
mutations of CARMA1 were also reported in patients with a
congenital lymphoproliferative disease known as BENTA (B-cell
expansion with NF-κB and T-cell anergy) syndrome (115–117)
(Figures 4A,B).
In some types of lymphomas, constitutive MALT1 activation
is achieved by mechanisms that bypass the classical CBM
signaling events. These include chromosomal translocations
involving the MALT1 or BCL10 genes, which are found
in MALT lymphomas (1). Such translocations can lead to
overexpression of the BCL10 or MALT1 genes or, more
frequently, to the generation of an oncogenic API2-MALT1
fusion protein. This fusion protein activates the classical
(canonical) and alternative (non-canonical) NF-κB pathways
through its scaffold and protease function thereby bypassing
the BCR-dependent upstream signaling events (1). The API2-
MALT1 fusion protein has constitutive protease activity and
cleaves NIK (76) and LIMA1α (75), two non-canonical MALT1
substrates recruited by the cIAP2 moiety (Figure 4C). NIK
cleavage leads to stabilization of NIK, which promotes activation
of the non-canonical NF-κB pathway by phosphorylation and
proteolytic maturation of the NF-κB2 precursor p100 into a
mature p52 NF-κB2 subunit (76). Cleavage of LIMA1α disrupts
the tumor suppressor function of this protein and promotes
B cell proliferation and adhesion via the cleavage of its Lim
domain, an LMO-like oncogenic protein (75) (Figure 4C). The
cleavage of NIK and LIMA1α seems to be a specific oncogenic
feature of the cIAP2-MALT1 fusion protein since it is not
known to be triggered by antigen receptor-mediated MALT1
activation.
Recently, we have uncovered a role for MALT1 protease
activity in the development of primary effusion lymphoma (PEL)
(118). PEL is a lymphoid tumor triggered by Kaposi’s sarcoma
herpes virus (KSHV), an oncogenic virus also known as human
herpes virus-8 (HHV8). KSHV-derived tumors derive from
latently infected B cells that are characterized by constitutive NF-
κB activation, which suppress the lytic program of the virus.
The latency program is controlled by different viral latency
genes such as K13 and K15, encoding a viral FLIP (Flice-
like inhibitory protein) homolog and a membrane protein
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homologous to the latent membrane protein 2A (LMP2A),
respectively. K13 and K15 induce constitutive activation of
NF-κB via the protease and scaffold activity of MALT1
(118) (Figure 4D). Pharmacological inhibition or silencing of
MALT1 leads to the reactivation of the viral lytic program
and induces cell death of PEL cell lines in vitro. MALT1
inhibitors also efficiently block the development of PELs and
induce their regression in vivo, in a xenograft model (118).
Interestingly, K13 and K15 contribute to MALT1 activation in
a CARMA1-independent manner (Figure 4D). Whether K13
and K15 mediate MALT1 activation via other CARMA/CARD
proteins, or in an entirely distinct manner, remains to be
explored.
MALT1 DEREGULATION IS ASSOCIATED
WITH ALLERGY, INFLAMMATORY SKIN
DISEASES AND CARCINOMA
Deregulations of MALT1 function are not restricted to the
above-described lymphoid pathologies but may also play wider
roles in allergies, psoriasis, and various non-lymphoid cancers
(Figure 1).
Evidence for a potential contribution of MALT1 to allergic
asthma comes from two studies showing that CARMA1 is
important in mouse models of allergic asthma (119, 120).
CARMA3 has also been shown to play an important role in
allergic airway inflammation in mice (121). The exact upstream
events triggering CBM activation in these models remain
undefined.
CARMA2/CARD14-mediated activation of MALT1 has been
shown to play a major role in the activation of human
keratinocytes upon exposure to the yeast cell wall component
zymosan or S. aureus (15). Interestingly, activating mutations
in the CARMA2-encoding gene CARD14 have been found to
be associated with development of psoriasis, an inflammatory
skin disease, in human patients (122, 123). Since then, an
increasing number of studies have reported genetic mutations
in CARD14 associated to psoriasis diseases (124). Some of the
CARD14 mutations found in patients were shown to enhance
NF-κB activation and promote secretion of CCL20 and IL-
8, two chemokines known to be associated with psoriasis
(123, 124). Similar to CARD11 mutations associated with
lymphoid malignancies, CARD14 mutations were mostly found
in the CC region. This suggests a similar mechanism of
activation, via induction of an active CARD14 conformation
and oligomerization necessary for CBM complex formation
and downstream signaling events. In support of this model,
a recent study showed that a single point mutation in
CARD14 E138A, which renders CARD14 hyperactive, was
sufficient to drive spontaneous psoriasis disease in mice (125).
Inhibition of MALT1 protease activity effectively reduces
cytokine and chemokine expression induced by overexpression
of this hyperactive CARD14 mutant in human primary
keratinocytes (126). Therefore, topical application of MALT1
inhibitors may be a future treatment option for psoriasis
patients.
Finally, an increasing number of publications support a role
for aberrant MALT1 signaling in the development of non-
lymphoid cancers, such as glioblastoma (127), breast cancer (18,
128, 129), melanoma (130), lung cancer (18), and various other
carcinomas (1, 131, 132). In these cancers, MALT1 seems to be
activated by constitutive signaling from GPCRs or the EGFR via
CARMA3 and/or by overexpression of MALT1 through various
mechanisms.
For breast cancer, two different subtypes, which are HER2 or
angiotensin II receptor (AGTR1) positive, have been described
to be addicted to CBM signaling via CARMA3 (18, 128, 129).
Interestingly, these two subsets show abnormal expressions of
AGTR1 or HER2 in a mutually exclusive manner (128). In
AGTR1 and HER2 positive breast cancer cell lines, NF-κB is
activated upon stimulation with Angiotensin II or the HER2
ligand heregulin, respectively, in a CARMA3-dependent manner
(18, 128, 129). Silencing of CBM components abrogates tumor
cell growth, migration, and invasion (18, 128, 129) and affects the
tumor microenvironment, since endothelial cell chemotaxis and
angiogenesis are abolished (128). AGTR1-positive breast cancers
represent 15–20% of all breast cancers (128) and HER2 positive
breast cancers form 20–25% of all breast cancers (18, 128, 129,
133). It remains possible that other breast cancer subtypes depend
on constitutive signaling by other GPCRs that can trigger NF-
κB signaling via CARMA3 (134). In addition to its relevance
in breast cancer, CARMA3 has been shown to play a role in
lung cancer (18). In this context, EGFR signaling via CARMA3,
BCL10, and MALT1 promotes tumorigenesis through effects
on NF-κB activation, cell proliferation, migration and invasion.
The relevance of the proteolytic activity of MALT1 was not
formally assessed in the above-citedmodels of breast cancer (128)
and lung cancer (18). It would thus be interesting to test the
potential effectiveness of pharmacological MALT1 inhibitors in
these models.
The relevance ofMALT1 as a protooncogene has been recently
extended to additional malignancies including melanoma (130)
and glioblastoma (127), in which MALT1 can be overexpressed.
Indeed, MALT1 is highly expressed in a subset of melanoma
associated with poor prognosis (130). MALT1 downregulation
or inhibition with the MALT1 inhibitor MI-2 (135), diminishes
the growth and the dissemination of melanoma cells in the
lung (130). While the proliferation of these melanoma cells is
NF-κB dependent, the dissemination is JNK/c-Jun-dependent
(130). In glioblastoma, it was shown that a subset of tumors
with poor outcome expresses low levels of the microRNA
miR181d, leading to high NF-κB activation. One of the targets of
miR181d is MALT1, which is highly expressed in the miR181d-
low tumors (127). Ectopic expression of miR181d and the
consequent downregulation of MALT1 suppresses growth of
tumor cells (127). These two studies suggest that, like in a
subset of MALT lymphomas (136), MALT1 overexpression per
se may play a role in promoting carcinogenesis, potentially
by spontaneous aggregation-mediated activation of MALT1.
Future studies should address how MALT1 promotes cellular
transformation in various cancers, whether and how specific
substrates of MALT1 contribute to tumorigenesis and if MALT1
inhibitors might be of therapeutic interest.
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MALT1 INHIBITORS MAY BE OF
THERAPEUTIC INTEREST FOR VARIOUS
PATHOLOGIES
Several recent studies have reported the development of
small molecule MALT1 inhibitors that act as active site or
allosteric inhibitors (135, 137–140). These have therapeutic
effects in preclinical (mouse) models of diffuse large B-cell
lymphoma, (135, 137, 138) and primary effusion lymphoma
(118). The idea that MALT1 inhibitors may be useful to
dampen inflammatory immune responses has received support
from studies using a mouse model of multiple sclerosis, in
which paralysis symptoms are alleviated by treatment with
a MALT1 inhibitor, or by genetic inactivation of MALT1
(13, 65, 85). The latter also protects mice from experimental
induction of colitis (13). Moreover, pharmacological inhibition
of MALT1 protects mice from LPS-induced inflammation and
lung injury, most likely through inhibitory effects on myeloid
cells (141). Nevertheless, the assumption that MALT1 inhibitors
will generally dampen immune responses has been challenged
by the observation that mice expressing a catalytically inactive
form of MALT1 have reduced numbers of natural Treg cells
and, as a consequence, progressively develop inflammatory
autoimmune disease (13, 14, 65, 66). This raises the interesting
possibility that, at least in the context of cancer, MALT1
inhibitors may exert their effects by a dual action on both
the inhibition of the growth of cancer cells and boosting anti-
tumor immune responses. Another possible field of application
for MALT1 inhibitors are inflammatory skin diseases such
as psoriasis, in which inhibitory effects on keratinocytes and
possibly on skin T cells may benefit the patients (15, 124–126).
As we progress in our knowledge about the molecular and
biological function of MALT1, future applications are likely to
emerge.
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